News

SomaLogic significantly expands key strategic collaboration with Novartis

Wednesday, October 23, 2019

Ten-year agreement with Novartis demonstrates broad and deep commitment to accelerating disease and therapeutic-specific insights based on proprietary proteomic technology

Boulder, Colo., USA — SomaLogic, Inc., announced today that it has entered into a new ten-year agreement with its long-time pharmaceutical partner, Novartis, to expand the application of SomaLogic’s leading proteomic technology across the company’s drug discovery and development efforts. The agreement includes plans to analyze at least 250,000 clinical samples from across the Novartis drug development portfolio.

“Our ongoing collaboration with our Novartis colleagues, which began in 2011 and was extended in 2014, has been instrumental in both developing and validating the value of our SomaScan Platform,” said Roy Smythe, M.D., CEO of SomaLogic. “Today, our technology is being used to inform research efforts around the world, promote individual health and wellness, and augment clinical decision-making.”

Under this new agreement, Novartis will expand its access to the SomaScan® Platform, which currently measures approximately 5000 human proteins in a small amount of biological sample. The SomaScan Platform enables Novartis to discover new insights into the biology of disease and the variability of drug response, develop new biomarkers that better target high-responder populations, and then apply these insights to the design of their clinical trials and commercial programs. In turn, this collaboration will assist SomaLogic to grow its clinical proteomics database and expand its growing pipeline of precision health information products. These products are aimed at helping individuals optimize their health and wellness as well as proactively manage many diseases and conditions.

“By continuing our collaboration with SomaLogic and incorporating proteomics into our development programs, alongside our genomics capabilities and deep analysis of our vast historical data resources, we aim to achieve unprecedented insight into human physiology,” said John Tsai, Head of Global Drug Development and Chief Medical Officer at Novartis. “Deciphering the complex interaction of protein networks in the body could unlock an additional therapeutic approach for treating the unmet needs of patients.”

Specific terms of the agreement, including financials and milestones, were not disclosed.

###

SomaLogic Contact:
Laura S. Mizoue, Ph.D.
Communications Specialist
+1.720.417.7509
lmizoue@somalogic.com

About SomaLogic
SomaLogic seeks to deliver meaningful and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from the precise, proprietary, and personalized measurement of health-related changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.

 
Continue Reading

Securisyn Medical Receives FDA 510(k) Clearance for its SolidAIRity™ III Airway Stabilization System

Monday, October 14, 2019

HIGHLANDS RANCH – October 9, 2019 – Securisyn Medical, LLC, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its SolidAIRity™ III Airway Stabilization System (“SolidAIRity™”) for airway management of patients requiring oral intubation. The company, dedicated to making airway management safer, has pioneered the first, fully integrated airway stabilization system designed and patented to provide unmatched airway stability for ventilated patients.
 

IM Therapeutics Raises $10 Million Financing Co-Led by JDRF T1D Fund and Morningside Ventures

Wednesday, October 09, 2019

IM Therapeutics Raises $10 Million Financing Co-Led by JDRF T1D Fund and Morningside Ventures  

AmideBio Awarded SBIR Phase II Grant to Further Development of its Novel Glucagons for the Treatment of Hyperinsulinism

Monday, September 30, 2019

BOULDER, CO, September 30, 2019 – AmideBio, LLC, a privately held biopharmaceutical company, announced today that it has received $1.56M in funding through a Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The goal of this two-year grant is to enable an Investigational New Drug (IND) filing with the FDA of a clinical candidate for the long term treatment of congenital hyperinsulinism. Several promising glucagon analogs were identified during the Phase 1 SBIR, and the Phase II grant will enable the final selection of a clinical candidate and preparation of an IND.

Congenital hyperinsulinism is a rare disease that affects newborns and results in persistent hypoglycemia which can lead to serious neurological complications inluding seizures and brain damage. Dr. Diva D. De León-Crutchlow, MD, MSCE, Chief of the Division of Endocrinology and Diabetes and Director of the Congenital Hyperinsulinism Center at Children's Hospital of Philadelphia (CHOP) will serve as a co-principal investigator on the grant. She is a recognized leader in the treatment of hyperinsulinism and in her role of co-PI, will provide the in vivo preclinical testing necessary for the program to progress to an IND stage.

“We are honored to receive this Phase II SBIR grant from the NIH. It is an acknowledgement of the success of our development under the Phase I SBIR and will allow us to complete our preclinical testing and produce sufficient therapeutic material to move forward with an IND,” said Pawel Fludzinski, CEO and President of AmideBio. “We are delighted to be able to continue to collaborate with Dr. Diva D. De LeónCrutchlow at CHOP who is a world leader in the treatment of CHI and brings significant expertise in the evaluation of potential drug candidates for this tragic disease.”

A solution-stable glucagon may also have potential benefits in the treatment of emergency hypoglycemia, for patients suffering from hypoglycemia after bariatric surgery and in an artificial pancreas for Type 1 and Type 2 diabetes treatment.

About AmideBio:
AmideBio has a pipeline of novel biotherapeutics generated by leveraging its knowhow to drive intelligent design of drug candidates targeting metabolic diseases. Its proprietary Cap-Clip™ technology delivers high-purity and difficult-to-manufacture BioPure™ peptides of any length with unprecedented purity for the pharmaceutical and biotech industry.

Contact:
Dr. Pawel Fludzinski
CEO & President
T: (505) 469-8466
pawel.fludzinski@amidebio.com
www.amidebio.com
 
Continue Reading

GREFFEX, Inc. Awarded $18.7 Million Contract with NIH to Develop a Plug-and-Play Technology Platform to Expedite Production of Vaccine Candidates for Biodefense and Emerging Infectious Diseases

Friday, September 27, 2019

GREFFEX, Inc. (Aurora, CO), a Fitzsimons Innovation Community company, is a transformative leader in genetic engineering. The company was recently awarded an $18.7 million contract with the National Institute of Health's (NIH) National Institute for Allergy and Infectious Diseases to develop and exploit its GreVac vaccine platform and expedite the production of vaccine candidates for biodefense and emerging infectious diseases. Through the support of the NIH contract, GREFFEX expects to advance the development of two of its influenza vaccines through clinical trials.
 

Boulder Based Edgewise Therapeutics Closes $50 Million Series B Financing

Tuesday, September 17, 2019

  

Nymbl Science Releases Their August Update

Monday, September 09, 2019

Below please find an overview of our progress for the month of August:

  • We continue to move forward towards closing out our round. We have about $235k remaining with 4 angel pitches lined up in the next two weeks.
  • We are excited to announce 3 new senior living customers and 2 successful implementations where greater than 25% of residents are actively participating.
  • We remain on track for 3 Medicare Advantage plan launches on January 1.
  • We have seen a doubling of the average number of weekly users across our Senior Living accounts. One new account has 61 weekly participants.

Two asks this time, both focused on sales talent:

  • Introductions to any sales people who have enterprise/mid-market SaaS experience and would be interested in working with Nymbl, either on a short term contract basis or as a full-time hire.
  • Introductions to anyone willing to advise us on enterprise SaaS sales.
 
Continue Reading

SomaLogic launches its first SomaSignal™ tests in select medical practices

Wednesday, September 04, 2019

Novel tests based on large-scale protein measurements will first offer personal and precise information about an individual’s cardiometabolic health status and trajectory  

Securisyn Medical Partners with Leading Medical Device Design and Development Firm, Meddux

Monday, August 12, 2019

HIGHLANDS RANCH, Colo., August 12, 2019 — Securisyn Medical, LLC, dedicated to inspiring the world to collaborate to make airway management safer, has announced a new partnership with Meddux™ Development Corp. to support the development of the Securisyn’s new product pipeline, including recent and ongoing contract awards through the U.S. Air Force (USAF) Small Business Innovation Research (SBIR) program. Meddux is a Colorado-based premier engineering design and development firm for complex medical devices, life sciences, and consumer healthcare products.  

Agilent Announces Purchase of Boulder Facility

Thursday, July 25, 2019

Agilent Technologies has announced it is purchasing the building in Boulder where they have been manufacturing therapeutic oligonucleotides (“oligos") for over a decade. This $12 million purchase, along with their recent $150 million investment in their second oligo manufacturing site in Frederick, Colorado, more than doubles their capacity to produce oligos and reaffirms Agilent’s confidence in the therapeutic oligo market. Furthermore, it solidifies their commitment to doing business in the state of Colorado and their commitment to be a good corporate citizen in local communities.